Remibrutinib treatment improves sleep and activity in chronic spontaneous urticaria patients: Phase 2b study results
L. Clore, V. Jain, A. Giménez-Arnau, K. Lheritier, P. Walsh, S. Haemmerle, M.
Maurer
Remibrutinib improves chronic spontaneous urticaria in patients irrespective of CU-Index: Results from Phase 2b study
W. Carr, K. Sitz, V. Jain, A. Giménez-Arnau, K. Lheritier, I. Nikolaev, S.
Haemmerle, M. Maurer
Remibrutinib improves chronic spontaneous urticaria in patients with low or high baseline IgE level
K. Hayama, A. Ramsey, M. Maurer, M. Hide, K. Lheritier, A. Zharkov, I. Nikolaev,
S. Haemmerle
Freedom from itch and hives in chronic spontaneous urticaria is associated with improved quality-of-life measures
J. A. Bernstein, A. Giménez-Arnau, M. Maurer, K. Sitz, G. Sussman, C-E.
Ortmann, M-M. Balp, T. Severin
Complete response with ligelizumab in chronic spontaneous urticaria: A composite score of symptoms and quality-of-life
J. A. Bernstein, A. M. Giménez-Arnau, M. Hide, M. Maurer, K. Sitz, G. Sussman,
P. Terradas-Montana, N. Barbier, T. Severin
Ligelizumab achieves freedom from disease activity in chronic spontaneous urticaria regardless of previous H1-antihistamine dose
W. Soong, K. Sitz, J. A. Bernstein, M. Maurer, A. M. Giménez-Arnau, E. Hua, T.
Severin
2020
Complete control of urticaria symptoms with ligelizumab helps normalize quality of life
J. A. Bernstein, M. Maurer, A. Giménez-Arnau, W. Soong, M. Metz, N. Barbier,
A. Barve, T. Severin, M-M. Balp, R. Janocha
Sleep and quality of life improves with better control of urticaria symptoms: Ligelizumab phase-2b studies
R. Janocha, A. Giménez-Arnau, M. Maurer, J. A. Bernstein, N. Barbier, E. Hua,
T. Severin, M-M. Balp
Ligelizumab achieves fast control of symptoms in numerically more patients with chronic spontaneous urticaria versus omalizumab
T. Severin, W. Soong, M. Maurer, A. Giménez-Arnau, M. Hide, J. A. Bernstein,
E. Hua, A. Barve, R. Janocha
Efficacy of ligelizumab in patients with chronic spontaneous urticaria inadequately controlled with omalizumab
G. Sussman, K. Sitz, M. Metz, M. Hide, M. Maurer, B. Barbier, E. Hua, R.
Janocha, T. Severin
2019
Ligelizumab reduces rescue medication use in patients with chronic spontaneous urticaria: Phase 2b study results
K. Sitz, W. Soong, B. Lanier, K. Kobayashi, A. Barve, E. Hua, R. Janocha, T.
Severin
Ligelizumab achieves sustained control of angioedema in patients with chronic spontaneous urticaria
W. Soong, B. Lanier, K. Sitz, K. Kobayashi, A. Barve, E. Hua, R. Janocha, T.
Severin
